FOLFOXIRI plus Bevacizumab for Metastatic Colorectal Cancer

February 5, 2015
Chiara Cremolini, MD

Special Reports, Gastrointestinal Cancers (Issue 4), Volume 4, Issue 1

Chiara Cremolini, MD, discusses the phase III TRIBE trial, which compared FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as for patients with metastatic colorectal cancer.

Chiara Cremolini, MD, a medical oncologist at the Tuscan Tumor Institute in Pisa, Italy, discusses updated results from the phase III TRIBE trial, which compared FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as a first-line treatment for patients with metastatic colorectal cancer (mCRC).

Clinical Pearls:

  • The study was used to compare progression-free and overall survival rates for patients with mCRC using FOLFOXIRI plus bevacizumab and FOLFIRI with bevacizumab.
  • Patients in the FOLFOXIRI arm achieved an overall survival rate of 29.8 months, versus 25.8 months for patients in the FOLFIRI arm.
  • 1 out of 4 ​patients who were given FOLFOXIRI plus bevacizumab had a survival rate of 5 years, as compared to 1 out of 8 patients who were treated with FOLFIRI plus bevacizumab.